Mubritinib Explained

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1] [2] [3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.

See also

Notes and References

  1. Book: McCormick F, Fabbro D . Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development) . Humana Press . Totowa, NJ . 2005 . 1-58829-384-X . 10.1385/1-59259-962-1:001.
  2. Book: Mitscher LA, Lednicer D . The organic chemistry of drug synthesis . Wiley . New York . 1977 . 0-470-10750-2 .
  3. Book: Lednicer D . Strategies for Organic Drug Synthesis and Design . Wiley-Interscience . New York . 2008 . 978-0-470-19039-5 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mubritinib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.